SCHEMBL147974

SCHEMBL147974

OB(O)c1occ2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37
ENPP2 Q13822 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
HSD17B10 Q99714 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
MGLL Q99685 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP2A6 P11509 1/20 0.35
TSHR P16473 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CYP1A2 P05177 1/20 0.33
HPRT1 P00492 1/20 0.32
PCSK9 Q8NBP7 1/20 0.32
ORAI1 Q96D31 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Magnesium Chloride Anhydrous SCHEMBL20694938 0.92 CA4 (0.32) CA4CA6CA5ACA7ENPP2
SCHEMBL8212797 0.82 CA4 (0.33) CA4CA6CA5ACA7ENPP2
SCHEMBL6013736 0.71 HSD17B10 (0.33) CA4CA6CA5ACA7ENPP2
SCHEMBL276957 0.70 CYP1A2 (0.42) HSD17B10TDP1KDM4EALDH1A1CYP2A6
SCHEMBL26639108 0.70 ALOX5 (0.34) CA4CA6CA5ACA7ENPP2
SCHEMBL15058729 0.69 PTPN1 (0.33) HSD17B10TDP1KDM4EALDH1A1CYP2A6
SCHEMBL28306537 0.68 CYP1A2 (0.41) HSD17B10TDP1KDM4EALDH1A1CYP2A6
SCHEMBL6531740 0.67 TSHR (0.37) HSD17B10TDP1KDM4EALDH1A1CYP2A6
SCHEMBL4079696 0.65 CYP2A6 (0.42) HSD17B10TDP1ALDH1A1CYP2A6TSHR
SCHEMBL21179481 0.65 ALDH1A1 (0.39) HSD17B10TDP1ALDH1A1CYP2A6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 609 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081946-A2 ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN Biovitrum AB (publ) (SE) 2009-07-29 EP claimed
WO-2008000745-A2 ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN BIOVITRUM AB (PUBL) (SE) 2008-01-03 WO claimed
US-12630522-B2 Compound for organic optoelectronic device, composition for organic optoelectronic device, and organic optoelectronic device and display device SAMSUNG SDI CO., LTD. (KR) 2026-05-19 US disclosed
US-12522813-B2 Mannanase for formulations having pH 5-12 BASF SE (DE) 2026-01-13 US disclosed
US-12492216-B2 Compound for organic optoelectronic device, composition for organic optoelectronic device, organic optoelectronic device and display device SAMSUNG SDI CO., LTD. (KR) 2025-12-09 US disclosed
US-20250339445-A1 Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke UNIV EMORY (US) 2025-11-06 US disclosed
EP-3787631-B1 MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS UNIV EMORY (US) 2025-09-10 EP disclosed
US-12410200-B2 Composition for organic optoelectronic device, organic optoelectronic device, and display device SAMSUNG SDI CO., LTD. (KR) 2025-09-09 US disclosed
US-20250234861-A1 LACTONES FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS BASF SE (DE) 2025-07-24 US disclosed
US-20250188053-A1 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES REATA PHARMACEUTICALS, INC. (US) 2025-06-12 US disclosed
US-12318393-B2 Modulators of orphan nuclear receptors for NASH and other metabolic disorders EMORY UNIVERSITY 2025-06-03 US disclosed
EP-1206457-A1 BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS ELI LILLY AND COMPANY (US) 2002-05-22 EP disclosed
WO-2002028837-A1 METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2002-04-11 WO disclosed
US-20020028938-A1 Prostaglandin endoperoxide H synthase biosynthesis inhibitors BLACK LAWRENCE A (US) 2002-03-07 US disclosed
WO-2002010137-A2 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARMACEUTICALS, INC. (US) 2002-02-07 WO disclosed
US-20020013318-A1 Prostaglandin endoperoxide H synthase biosynthesis inhibitors BLACK LAWRENCE A (US) 2002-01-31 US disclosed
US-6307047-B1 PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ABBOTT LABORATORIES 2001-10-23 US disclosed
EP-1124804-A1 PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-08-22 EP disclosed
WO-2001016120-A1 BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS ELI LILLY AND COMPANY (US) 2001-03-08 WO disclosed
WO-2000024719-A1 PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS ABBOTT LABORATORIES (US) 2000-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492216-B2 Compound for organic optoelectronic device, composition for organic optoelectronic device, organic optoelectronic device and display device OCIAD2, OCIAD1, OXER1 CA4 1590/4885CA6 1207/4885CA5A 4466/4885
US-20250234861-A1 LACTONES FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS CYP51A1, LSS, OLA1 CA4 3794/4885CA6 3874/4885CA5A 1786/4885
US-20020028938-A1 Prostaglandin endoperoxide H synthase biosynthesis inhibitors PTGS1, PTGIS, PTGS2 CA4 4813/4885CA6 4571/4885CA5A 953/4885
US-12410200-B2 Composition for organic optoelectronic device, organic optoelectronic device, and display device OCIAD2, OR10J3, OCIAD1 CA4 1212/4885CA6 1141/4885CA5A 4292/4885
US-12318393-B2 Modulators of orphan nuclear receptors for NASH and other metabolic disorders RORA, RORB, RORC CA4 3429/4885CA6 2811/4885CA5A 1365/4885
US-20250339445-A1 Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke RXRA, RXRG, RXRB CA4 2860/4885CA6 2818/4885CA5A 3669/4885
US-12630522-B2 Compound for organic optoelectronic device, composition for organic optoelectronic device, and organic optoelectronic device and display device OXER1, OR10J3, CHRM1 CA4 1450/4885CA6 1641/4885CA5A 4657/4885
US-20250188053-A1 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES RORC, RORB, RORA CA4 4247/4885CA6 3945/4885CA5A 2000/4885
US-20020013318-A1 Prostaglandin endoperoxide H synthase biosynthesis inhibitors PTGS1, PTGIS, PTGS2 CA4 4813/4885CA6 4571/4885CA5A 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.